Sanofi SA vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Sanofi SA trades at $44.05 (market cap $104.83B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $58.85. The key difference: Sanofi SA pays a 5.5% dividend while Vanguard Emerging Markets Stock Index Fund ETF pays none, and Vanguard Emerging Markets Stock Index Fund ETF is trading nearer its 52-week high, Sanofi SA nearer its low. Which is the better fit depends on your goals.
| SNY | VWO | |
|---|---|---|
Market Cap | $104.83B | — |
Sector | Health | — |
52-Week High | $52.34 | $61.24 |
52-Week Low | $41.33 | $49.54 |
Enterprise Value | $121.32B | — |
Dividend Yield | 5.5% | — |
Trailing returns across standard periods
Latest headlines on both assets
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →